Future of HIV vaccine research Voronin et al. 415 Figure 1 Examples of recent progress in HIV vaccinology (a) Mosaic sequences encompassing a wide array of virus sequences are exhibiting increased breadth and depth of responses, two key features of a desirable immunogen, in NHP trials [2 ]. Preclinical studies of an MVA-based HIV vaccine candidate demonstrate efficient antigen presentation and some antiviral effect [3 ]. (b) Approaches tested in NHPs show protection against SIV challenge [4 ,5 ]. (c) The results of RV144 demonstrated a modest protection (31%) against acquisition of HIV [1 ]. (d) Analysis of the Step vaccine candidate shows a sieve effect on breakthrough viruses, suggesting that the vaccine was able to induce immune responses targeting the incoming virus [6 ]. (e) Analyses of viral sequences following acute infection show that one or a few viruses usually establish infection [7]. (f) Different adjuvants induce increased mucosal protection through induction of both innate and adaptive immunity [8 ]. (g) Discovery of additional broadly NAbs with new epitope targets suggests novel approaches for rational immunogen design [9 ]. (h) Systems biology approaches have begun to provide insights into the mechanisms and signatures of protection after vaccination and the signatures of progression to AIDS [10 ,11 ]. MVA, modified vaccinia virus Ankara; NAbs, neutralizing antibodies; NHPs, nonhuman primates; SIV, simian immunodeficiency virus.
Introduction
This time is an important moment in HIV vaccine research. The result of the trial in Thailand (RV144), showing for the first time that a vaccine can confer protection (albeit limited) against HIV acquisition, has provided an important proof of concept that a vaccine against HIV is possible [1 ] . In addition, it comes at the same time as a steadily increasing flow of important laboratory results, including new insights into the human immune response to HIV and the virus's attempt to evade it, technological advances that have facilitated the isolation of broadly neutralizing antibodies (NAbs) against HIV, the demonstration of the critical role of CD8 þ effector memory T cells in conferring protection in nonhuman primates, detailed insights into the role of the mucosa both as a physical and immunological barrier to HIV infection and novel strategies for vaccine design based on the evolutionary analysis of viral sequences in infected individuals ( Fig. 1 [1 ,2 -6 ,7,8 -11 ] ). Together, these clinical and laboratory advances have created a new momentum and optimism in the field. In the context of this fundamentally changed landscape, this article will discuss the origins, past contributions, and future role of the Global HIV Vaccine Enterprise (the Enterprise; www.vaccineenterprise.org) (Fig. 2) .
The Global HIV Vaccine Enterprise
The Enterprise is a voluntary alliance of independent organizations committed to working together to accelerate the development of a preventive HIV vaccine. The creation of the Enterprise in 2003 was an unprecedented response to the daunting scientific challenges of developing an HIV vaccine.
In spite of over a quarter of a century of international efforts to control the HIV epidemic, HIV/AIDS continues to pose the greatest health challenge facing humanity today. Approximately 33 million people are living with HIV worldwide and 25 million people have died of AIDS since the beginning of the epidemic in 1981. Sub-Saharan Africa remains the region most heavily affected by HIV, accounting for 67% of all people living with HIV, and AIDS-related illness remains a leading cause of death worldwide [12] .
Various strategies are being pursued to prevent transmission and/or acquisition of the virus, including behavioral interventions and education, microbicides, preexposure prophylaxis, and treatment as prevention [13] . Vaccines are recognized as the most cost-effective and highest-impact public health intervention to control a wide variety of viruses and bacteria and thus, developing a safe and effective vaccine against HIV must be one of our greatest public health priorities. However, HIV has proven to be a difficult adversary with a remarkable combination of strategies for both suppressing and evading the host immune response. Its extraordinary genetic diversity, the complex properties of its envelope glycoprotein, and its unique ability to infect and induce the death of the cells in the human immune system (CD4 þ T helper cells) required for an effective immune response have together posed unprecedented challenges for vaccine development.
In 2002, the overall landscape of HIV vaccine research reflected traditional and mostly successful approaches to control other viruses: multiple governmental and philanthropic organizations from around the world were independently funding basic and translational research efforts, largely pursued by individual investigators. However, frustrated by the pace of progress, a group of leaders met in 2003 to discuss the best and fastest way forward. Out of those discussions emerged a proposal to create a global alliance tasked with catalyzing and overseeing a more coordinated approach to HIV vaccine research and development [14] . The need for creation of such a structure, termed the Global HIV Vaccine Enterprise, stemmed from a shared view that the strength of existing efforts was largely limited to single-investigator approaches to fundamental vaccine research and that the field would benefit from the development of a high-level shared vision of the best way forward. Whereas the insights and discoveries of independent investigators are necessary for driving progress in the field, there was a growing appreciation that such efforts alone were not sufficient. For example, the collaborative efforts required 416 HIV vaccines after STEP 
The Enterprise Scientific Strategic Plan
The Plan, developed by the Enterprise Council, the body charged with guiding the directions and activities of the alliance, presents opportunities to advance HIV vaccine research and development through approaches that require increased global collaboration, thus building on and complementing critical contributions from individual researchers. Although the Plan is not prescriptive in nature, the vision of the Enterprise assumes shared accountability of members for implementing the Plan's high-level goals and priorities. In addition, other stakeholders involved in controlling the HIV epidemic and more directly in HIV vaccine research and development are encouraged to align their activities with the Plan.
In 2005, the Enterprise published its first Plan [15] . The culmination of a broad consultative process, the Plan identified six priority areas and emphasized the need for greater collaboration both among funders and researchers. Aligned with and supporting both the specific and overall themes of the Plan, several new research initiatives were started, including the Center for HIV/AIDS Vaccine Immunology (CHAVI) established by NIAID, and the Collaboration for AIDS Vaccine Discovery (CAVD), a compendium of 18 consortia, established by the Gates Foundation. The CHAVI collaboration has brought together 91 researchers from nine countries and 43 institutions to understand the early events that follow acute HIV infection. The resources available to the collaboration have allowed large-scale projects that could not have been achieved by individual laboratories or small collaborations, especially without the easy access to samples from shared cohorts. In addition to the many scientific projects underway in CAVD, the collaboration includes a set of shared core facilities, which provide validated standardized assays and methods to the field. The expertise of these facilities ranges from statistical analyses to mouse immunology and antibody assays. To support collaboration, WHO-UNAIDS and AVAC: the Global Advocacy for HIV Prevention, hosted by the Enterprise, formed a Coordinating Group and a Communications Sub-group to prepare for the release of HIV vaccine efficacy trial results. These structures now serve as fora for greater dialogue between different funders and researchers (Fig. 2 ).
Since 2005, HIV vaccine research has changed fundamentally, both in how it is organized, the science being undertaken, and, most importantly, recent discoveries ( Fig. 1 ). As noted in the Introduction section and Fig. 1 , new laboratory and clinical results are charting new directions for exploration and providing new momentum for the field. It was in the context of this changing landscape that the Enterprise embarked on an evaluation of the impact of the 2005 Plan and development of the 2010 Plan. Similar to the process used in development of the 2005 Plan, the perspectives of the scientific community on major challenges in the field were gathered through discussions of the Enterprise Science Committee, five Working Groups and consultations at major conferences, involving over 400 scientists in the process. The Enterprise Council then reviewed and discussed input from the community and developed the 2010 Plan.
Rethinking the centrality of clinical trials
The Enterprise discussions, leading up to the 2010 Plan, reached broad agreement that now was the time to fundamentally rethink the purpose, nature and organization of clinical trials. As in many other areas of health research, basic discovery and clinical research on HIV vaccines are largely performed as separate activities, funded by different mechanisms, and carried out by investigators with different backgrounds and training. The integration of fundamental and clinical research has sometimes been referred to as 'translational research'. However, this term connotes a process whereby groups working separately come together at appropriate moments to discuss opportunities to translate the results from one field to another. This process is intrinsically inefficient, as it assumes that one knows when an appropriate moment has arrived and, for clinical efficacy trials, it precludes the necessary pretrial planning of what hypothesis should be tested and what immunological and virological assays should be carried out, from which tissues and at what time points. Although these questions were discussed before the start of the Step and RV144 trials, an understanding of the immunological basis for the clinical results observed in these trials is coming from post-hoc analysis of clinical samples provided to the global scientific community through a novel and commendable peer-review process. One lesson from this process has been an appreciation of the critical importance of the laboratory and epidemiological analysis to understand the clinical efficacy data. Without that analysis, there is no opportunity of acquiring insights into the signatures or correlates of protection, of discerning whether the vaccine elicited an immune response that exerted any selection pressure on the virus and what the impacts were of other parameters such as circumcision, sex, risk behavior and so on to response. At the same time, it is recognized that robust scientific enquiry as an integral part of human trials requires additional resources and will increase the complexity of trial design and the importance of community engagement.
A common view that emerged from the Working Groups that have been discussing the 2010 Plan was that clinical trials represent a unique opportunity to gain insights into the mechanisms of immunological protection against HIV and to define the relevance of a variety of immune responses to vaccine efficacy in humans. In short, human clinical trials should be viewed both as an integral and necessary part of scientific exploration, as well as the only definitive way of advancing promising vaccine candidates along a development pathway. This scientifically enriched approach to human trials requires integrated teams of researchers that include investigators with both laboratory and clinical trials expertise.
The centrality of human efficacy trials to the discovery and development process has other important implications. As stressed by the Working Groups, it has become critical that the field undertakes more efficacy trials.
Since HIV was discovered, there have only been four large-scale human efficacy vaccine trials [1 ,16,17] , a number that is insufficient to explore diverse vaccine concepts in humans, and certainly does not reflect the urgency of the epidemic.
Data sharing
Clinical trials with a robust laboratory component generate enormous amounts of data, which, if mined fully, can yield important insights into vaccine immunogenicity and efficacy, as well as the relative importance of various behavioral, genetic, and biological risk factors for acquisition. In order to take maximum advantage of these valuable data, the Working Groups stressed the importance of quality, relational and open-access databases. Recent progress in high-throughput data collection has led to the creation of multiple databases with a diversity of deposition protocols, file formats and metadata terms. These databases are managed and mostly maintained by data-producers. The limitations of existing systems include the inability to compare datasets obtained independently, the lack of cross-reference between different datasets and data types and the frequent lack of access to data. Development of common standards for data deposition and shared tools for data analysis would tremendously facilitate the discovery and development process. Several Enterprise partners have started dialogues to facilitate the coordinated approach of data access and deposition and these efforts will receive more attention in the near future.
Optimizing existing and moblilizing new resources
The objectives outlined above will not be reached without optimizing the use of existing and attracting new resources. Currently, financial support for HIV vaccine research and development primarily comes from a very limited number of funders. Many countries and regions of the world possess significant human, scientific, and financial resources that could be focused to help address the global HIV epidemic. One goal of the Enterprise and the Plan is, therefore, to provide a mechanism through which new partners can be engaged and can maximize the impact of their contributions. Industry is particularly important if we are to move promising vaccine concepts into the development and licensure pipeline. By developing a comprehensive picture of the global effort, the Plan identifies key gaps and opportunities that need additional attention. Thus, the Plan provides a vehicle both to attract new resources and to ensure that their impact has the most benefit.
Regional initiatives
For this reason (among others), the Enterprise is supporting the development of regional initiatives whose goals are to consolidate and mobilize local resources and build critical mass. One such initiative is the African AIDS Vaccine Program (AAVP), which was formed with the support of several Enterprise partners, including the WHO-UNAIDS, the Canadian International Development Agency (CIDA) and IAVI. AAVP aims to build capacity within four centers of excellence established throughout the African continent. Alignment of AAVP priorities with the Enterprise Plan provides the framework for significant contributions of African scientists to the global effort. It also serves as a powerful advocacy tool, both for strengthening commitment of African governments and for increasing local community involvement in all aspects of HIV vaccine research and development. Finally, the spirit of collaboration fostered by the values of the Enterprise promotes sharing of resources within African scientific networks and exchange of information and human resources between the north and the south. A similar initiative is currently under development for Asia, where the AIDS Vaccine for Asia Network (AVAN) aims to bring together scientists across Asia and capitalize on the rapidly growing scientific potential in the region.
New minds, new ideas
In addition to the regional initiatives, the Enterprise has launched the New Minds, New Ideas initiative to nurture and attract young and early career investigators as well as investigators from other fields. The goals of this initiative are to raise awareness of the importance of young scientists to the field and to suggest strategies for addressing the exceptional challenges young scientists are currently facing on the path to becoming independent researchers. The increasingly multidisciplinary nature of biomedical research is one of the challenges facing young investigators, as it requires a very diverse array of expertise ranging from basic immunology to clinical trial design and computational analysis. Multidisciplinary team research is transforming biomedical science, so that even the concept of independence itself is currently undergoing change. Team science and consortia are becoming the norm and especially so in the HIV vaccine field. This changing landscape raises multiple questions about attribution of credit, mentorship, and career opportunities for young scientists within these teams. First and foremost, these challenges have to be recognized by established researchers in the field, whose guidance and mentorship is essential to ensure that scientific excellence is maintained in the future. The Enterprise, in collaboration with Online Collaborative Training for AIDS Vaccine Evaluation (OCTAVE), is launching a series of multidisciplinary training workshops as part of its New Minds, New Ideas Initiative.
Conclusion
This moment is an extraordinary time in HIV vaccine research. New concepts for vaccine design are emerging from many different directions. And these novel ideas for vaccine design are surfacing at the same time as the results of RV144 have provided proof of concept that it is possible for a vaccine to confer protection against HIV infection. In addition, powerful new technologies from other areas of biomedical research are creating new opportunities for vaccine design and analysis. The convergence of these three streams has important implica-tions for the future of the field: science without the possibility of vaccine-induced protection is tantalizing but ultimately of no public health value, whereas the proof of concept demonstration that a vaccine can confer limited protection is only of value if there is the possibility of improving on the results of the RV144 trial. It is the role of the Enterprise -that is the organizations and individuals who form the alliance -to ensure that this special moment is not lost and that we capitalize to the fullest on the opportunities that lie ahead.
